Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives

Sabrina Bimonte, Vittorio Albino, Mauro Piccirillo, Aurelio Nasto, Carlo Molino, Raffaele Palaia, Marco Cascella

Research output: Contribution to journalReview article

Abstract

Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the deadliest cancers worldwide. Despite orthotopic liver transplantation and hepatic resection representing the principal lines of treatment for this pathology, only a minority of patients can be resected owing to cirrhosis or late diagnosis. Keeping in mind the end goal of conquering these challenges, new alternative approaches have been proposed. Accumulating evidence has demonstrated that epigallocatechin-3-gallate (EGCG), the principal catechin of green tea with multiple biological properties, is able to modulate different molecular mechanisms underlying HCC, mainly through its antioxidant activity. In this article, we revise these findings reported in the literature, in order to highlight the potential roles of EGCG in the treatment of HCC. The CAMARADES criteria were applied for quality assessment of animal studies, and a narrative synthesis performed. New bits of information available for translational perspectives into clinical practice are addressed.

Original languageEnglish
Pages (from-to)611-621
Number of pages11
JournalDrug Design, Development and Therapy
Volume13
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Hepatocellular Carcinoma
Catechin
Liver
Delayed Diagnosis
Tea
Liver Transplantation
Neoplasms
Fibrosis
Therapeutics
Antioxidants
Pathology
epigallocatechin gallate

Keywords

  • epigallocatechin-3-gallate
  • hepatocellular carcinoma
  • preclinical studies
  • tumor progression

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

@article{3eaf86dfbb264ccf9699c44cc53525ff,
title = "Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives",
abstract = "Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the deadliest cancers worldwide. Despite orthotopic liver transplantation and hepatic resection representing the principal lines of treatment for this pathology, only a minority of patients can be resected owing to cirrhosis or late diagnosis. Keeping in mind the end goal of conquering these challenges, new alternative approaches have been proposed. Accumulating evidence has demonstrated that epigallocatechin-3-gallate (EGCG), the principal catechin of green tea with multiple biological properties, is able to modulate different molecular mechanisms underlying HCC, mainly through its antioxidant activity. In this article, we revise these findings reported in the literature, in order to highlight the potential roles of EGCG in the treatment of HCC. The CAMARADES criteria were applied for quality assessment of animal studies, and a narrative synthesis performed. New bits of information available for translational perspectives into clinical practice are addressed.",
keywords = "epigallocatechin-3-gallate, hepatocellular carcinoma, preclinical studies, tumor progression",
author = "Sabrina Bimonte and Vittorio Albino and Mauro Piccirillo and Aurelio Nasto and Carlo Molino and Raffaele Palaia and Marco Cascella",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/DDDT.S180079",
language = "English",
volume = "13",
pages = "611--621",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma

T2 - experimental findings and translational perspectives

AU - Bimonte, Sabrina

AU - Albino, Vittorio

AU - Piccirillo, Mauro

AU - Nasto, Aurelio

AU - Molino, Carlo

AU - Palaia, Raffaele

AU - Cascella, Marco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the deadliest cancers worldwide. Despite orthotopic liver transplantation and hepatic resection representing the principal lines of treatment for this pathology, only a minority of patients can be resected owing to cirrhosis or late diagnosis. Keeping in mind the end goal of conquering these challenges, new alternative approaches have been proposed. Accumulating evidence has demonstrated that epigallocatechin-3-gallate (EGCG), the principal catechin of green tea with multiple biological properties, is able to modulate different molecular mechanisms underlying HCC, mainly through its antioxidant activity. In this article, we revise these findings reported in the literature, in order to highlight the potential roles of EGCG in the treatment of HCC. The CAMARADES criteria were applied for quality assessment of animal studies, and a narrative synthesis performed. New bits of information available for translational perspectives into clinical practice are addressed.

AB - Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the deadliest cancers worldwide. Despite orthotopic liver transplantation and hepatic resection representing the principal lines of treatment for this pathology, only a minority of patients can be resected owing to cirrhosis or late diagnosis. Keeping in mind the end goal of conquering these challenges, new alternative approaches have been proposed. Accumulating evidence has demonstrated that epigallocatechin-3-gallate (EGCG), the principal catechin of green tea with multiple biological properties, is able to modulate different molecular mechanisms underlying HCC, mainly through its antioxidant activity. In this article, we revise these findings reported in the literature, in order to highlight the potential roles of EGCG in the treatment of HCC. The CAMARADES criteria were applied for quality assessment of animal studies, and a narrative synthesis performed. New bits of information available for translational perspectives into clinical practice are addressed.

KW - epigallocatechin-3-gallate

KW - hepatocellular carcinoma

KW - preclinical studies

KW - tumor progression

UR - http://www.scopus.com/inward/record.url?scp=85062820296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062820296&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S180079

DO - 10.2147/DDDT.S180079

M3 - Review article

C2 - 30858692

AN - SCOPUS:85062820296

VL - 13

SP - 611

EP - 621

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -